Rani Therapeutics files Form 3 for CFO Nicholas Maestas on initial beneficial ownership statement

Rani Therapeutics named Nicholas Maestas as chief financial officer in an initial Form 3 filing dated June 29, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001871423-26-000008), on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Rani Therapeutics Holdings Inc. filed a Form 3 with the SEC on June 29, 2026, reporting initial beneficial ownership for newly appointed Chief Financial Officer Nicholas Maestas. The filing was published via EDGAR on July 8, 2026.

Rani Therapeutics named Nicholas Maestas as chief financial officer in an initial Form 3 filing dated June 29, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001871423-26-000008), on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here